September 17 - 18

Target Identification and Validation

Lead Generation Strategies

Emerging Ubiquitin and Autophagy Targets

Targeting NASH

Immuno-Oncology: Emerging Targets and Therapeutics

NEW

Antibodies Against Membrane Protein Targets – Part 1

Antibody Forum – Part 1

Targeting GPCRs for Drug Discovery

An In-Depth Introduction to Drug Metabolism and Applications to Discovery and Development

September 18 - 19

RNA as a Drug Target

NEW

Kinase Inhibitor Discovery

PROTACs and Targeted Protein Degradation

NEW

Targeting Fibrosis

NEW

GPCR-Based Drug Discovery

Antibodies Against Membrane Protein Targets – Part 2

Antibody Forum – Part 2

Introduction to Small Molecule Drug Discovery and Development

Practical Phenotypic Screening

Plenary Keynote Program

Featured Speakers

About the Event

The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,300 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules. Delegates can customize their experience at the event by choosing from 14 conference programs, plus focused training seminars, comprehensive short courses, moderated roundtables and networking functions to meet their own research needs and those of their organizations.

Additions for 2019 include new programming dedicated to PROTACs and their applications, drugs and targets in fibrosis, novel immune-oncology targets, RNA as an emerging target for small molecule drugs, along with expanded coverage of protein engineering and novel biotherapeutics.